Friday, February 22, 2019
IBB 109.15 1.95 (1.76%)XBI 84.09 1.21 (1.42%)
Ticker Current Price Change Graph
IBB 109.15 1.95 (1.76%)
XBI 84.09 1.21 (1.42%)
Last updated: ago
Sign in to Endpoints
Menu Search Chat
  • Special Reports
  • Events
  • ENDPOINTS 100
  • News
  • Protocols
  • Bioregnum
  • Endpoints Careers
  • About
  • Advertise
  • Privacy Policy
  • Reader center

Dear Bernie: Catalyst CEO McEnany defends his $375,000 price tag on an old drug once offered for free

by John Carrollenvelope — on February 21, 2019 10:13 AM EST
Updated: 10:31 AM

UPDATED: Merck’s Roger Perlmutter pays $300M to scoop up a battered Immune Design for its I/O work

by John Carrollenvelope — on February 21, 2019 07:10 AM EST
Updated: 09:23 AM

MPM adds $408M for its next big wave of biotech startups — and oncology still dominates the menu

by John Carrollenvelope — on February 21, 2019 07:09 AM EST

J&J steps up alongside AbbVie to partner with fast-growing Morphic on its small molecule approach to integrins

by John Carrollenvelope — on February 21, 2019 06:38 AM EST

Applying CRISPR to Duchenne, Duke researchers spotlight 1-year mouse data in Sarepta-sponsored study

by Amber Tongenvelope — on February 20, 2019 09:52 AM EST
Updated: 09:56 AM

Deaths spur partial hold for Xencor’s CD3 bispecific for leukemia, partnered with Novartis in $2.5B deal

by John Carrollenvelope — on February 20, 2019 08:14 AM EST
Updated: 08:23 AM

Stem cell therapies for space missions? Pluristem joins forces with NASA to combat space-related ailments

by Natalie Groverenvelope — on February 20, 2019 07:31 AM EST
Updated: 07:33 AM

Pfizer drops 10 mg dose of best-selling Xeljanz as study spotlights cardio safety issue, higher rate of deaths

by John Carrollenvelope — on February 20, 2019 06:17 AM EST
Updated: 01:13 PM

Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light

by John Carrollenvelope — on February 19, 2019 07:02 PM EST
Updated: 07:08 PM

Stock activists fire back at Allergan’s defensive moves, push for a company sale

by John Carrollenvelope — on February 19, 2019 01:13 PM EST
Updated: 01:56 PM

  • 1
  • 2
  • 3
  • 226

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
  • Endpoints Careers
  • About Endpoints
  • Privacy Policy
  • Advertise

copyright 2019 Endpoints Company

Yes, I'd like to subscribe No, thanks
I'm already a subscriber
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
Sure No
← Go back

Sign in to Endpoints News

I forgot my password Request a magic link
← Go back

Request a magic link

Enter your email below to get a Magic link which lets you sign in quickly without using a password.
Please note the Magic link is one-time use only and valid for only 24 hours.
← Go back

Set a new password

We will send you a link, with which you will be able to set a new password.
Please note this link is one-time use only and valid for only 24 hours.